Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies

Cursano, M.C.; Valsecchi, A.A.; Pantano, F.; Di Maio, M.; Procopio, G.; Berruti, A.; Bertoldo, F.; Tucci, M.; De Giorgi, U.; Santini, D.; Altavilla, Amelia; Atzori, Francesco; Banna, Giuseppe Luigi; Barni, Sandro; Basso, Umberto; Bauckneht, Matteo; Berardi, Rossana; Berruti, Alfredo; Bertoldo, Francesco; Bimbatti, Davide; Boccardo, Francesco; Buti, Sebastiano; Buttigliero, Consuelo; Caffo, Orazio; Calabrò, Fabio; Cattrini, Carlo; Cellini, Francesco; Conteduca, Vincenza; Cursano, Maria Concetta; De Feo, Giulia; De Giorgi, Ugo; Di Lorenzo, Giuseppe; Di Maio, Massimo; Di Napoli, Marilena; Ermacora, Paola; Fornarini, Giuseppe; Fratino, Lucia; Fusco, Vittorio; Gernone, Angela; Ibrahim, Toni; Lanzetta, Gaetano; Malgeri, Andrea; Maruzzo, Marco; Masini, Cristina; Messina, Carlo; Mosca, Alessandra; Naglieri, Emanuele; Nolè, Franco; Ortega, Cinzia; Palermo, Andrea; Pantano, Francesco; Prati, Veronica; Procopio, Giuseppe; Rescigno, Pasquale; Roberto, Michela; Rossetti, Sabrina; Roviello, Giandomenico; Santini, Daniele; Stellato, Marco; Tambaro, Rosa; Toma, Ilaria; Tucci, Marcello; Valsecchi, Anna Amela; Verzoni, Elena; Zanardi, Elisa; Zucali, Paolo Andrea

doi:10.1016/j.esmoop.2024.103484

ESMO Open

2024

DOI: 10.1016/j.esmoop.2024.103484

|View full text |Cite

Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies

M.C. Cursano,

A.A. Valsecchi,

F. Pantano

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 126 publications

(211 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Bone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies

Alshehri

2024

Diagnostics

View full text Add to dashboard Cite

Recent advances have broadened the range of therapeutic options for mCRPC, with several new treatments, including novel hormonal therapies (enzalutamide, abiraterone), chemotherapeutic agents (docetaxel, cabazitaxel), immunotherapies (sipuleucel-T), and bone targeting radiopharmaceuticals (radium-223) showing improved clinical outcomes and receiving U.S. Food and Drug Administration approval. These new treatments provide new avenues for improving patient survival and quality of life. Radium-223, a targeted alpha-emitter, specifically targets bone metastases, offering palliative benefits and a potential increase in life expectancy. The integration of radium-223 with other treatments shows promise for managing mCRPC. However, the optimal sequencing and combination of radium-223 with other therapies are still being explored, with various clinical trials investigating new therapeutic approaches. The integration of these therapies, especially to provide more effective, personalized treatment strategies, requires further investigation. A thorough literature review was conducted on current treatments for mCRPC, including chemotherapeutic agents, oral hormonal therapies targeting the androgen receptor axis, immunotherapies, and radium-223. Ongoing clinical trials investigating radium-233 in the context of other therapies for the treatment of mCRPC patients were also reviewed. Further studies should focus on determining the optimal sequencing and dosing and identifying biomarkers that predict treatment response to enhance outcomes of mCRPC patients. This review underlines the rational strategies of combining radium-223 with other therapies, investigating their impact on bone in terms of delaying skeletal-related events, and managing bone disease progression in mCRPC patients.

show abstract

Bone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies

Alshehri

2024

Diagnostics

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies

Cited by 1 publication

References 126 publications

Bone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies

Bone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies

Contact Info

Product

Resources

About